Red blood cell transfusion, danazol therapy, or thalidomide are recommended for patients who develop anemia. Ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), can reduce the splenomegaly and the constitutional symptoms of weight loss, fatigue, and night sweats for patients with Janus kinase 2 (JAK2)-positive or Janus kinase 2 (JAK2)-negative primary<unk>  (PMF), post–essential thrombocythemia<unk> , or post–polycythemia vera<unk> . Hydroxyurea, chemotherapy, or radiotherapy are recommended for patients who develop splenomegaly.
Myelofibrosis medical therapy
Aplastic anemia medical therapy
Myeloproliferative neoplasm medical therapy
POEMS syndrome medical therapy
Multiple myeloma medical therapy
Myelodysplastic syndrome medical therapy
Thrombocytopenia medical therapy
Acute myeloid leukemia medical therapy